On September 27, 2023 AbCellera (Nasdaq: ABCL) reported two upcoming poster presentations on its T-cell engager platform at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023 (Press release, AbCellera, SEP 27, 2023, View Source [SID1234635488]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We have made significant progress on the application of our T-cell engager platform since we presented data at SITC (Free SITC Whitepaper) in 2022," said Bo Barnhart, Ph.D., VP, Translational Research at AbCellera. "We’re looking forward to presenting two posters this year demonstrating how key insights into CD3 T-cell engager biology help us to execute on our programs for various tumor targets, including a challenging peptide-MHC target."
Details on AbCellera’s poster presentations at SITC (Free SITC Whitepaper) are as follows:
Title: A rational approach for selecting CD3-binding antibodies for T-cell engager development
Abstract Number: 1367
Date and Time: Friday, November 3 from 9:00 a.m. to 7:00 p.m. PDT
Location: San Diego Convention Center, Exhibit Halls A and B1 or online at View Source
Title: Targeting intracellular tumor antigens to fight cancer: Discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC
Abstract Number: 1395
Date and Time: Friday, November 3 from 9:00 a.m. to 7:00 p.m. PDT
Location: San Diego Convention Center, Exhibit Halls A and B1 or online at View Source
About T-Cell Engagers
CD3 T-cell engagers are bispecific antibodies that guide the immune system to find and eliminate cancer cells by binding both cancer-killing T cells and tumor targets at the same time. Developing effective T-cell engagers requires two parental antibodies—a CD3-binding arm that fine-tunes T-cell activation and a tumor-binding arm with high specificity for cancer cells. The small number of available CD3-binding antibodies that can effectively fine-tune T-cell responses has been a barrier to T-cell engager development. To address this barrier, AbCellera developed a complete T-cell engager platform that includes fully human, developable CD3-binding antibodies with unique binding and functional properties. By combining these antibodies with OrthoMabTM, its clinically validated multispecific engineering platform, and its antibody discovery and development engine, AbCellera’s T-cell engager platform is designed to bring new cancer medicines to the clinic faster.